The administration of complement component C9 enhances the survival of neonatal rats with Escherichia coli sepsis.
To determine the significance of neonatal C9 deficiency, an animal model was developed in the rat. By rocket immunoelectrophoresis, the concentration of C9 in pooled adult rat serum was 224 +/- 7.2 microg/mL. In contrast, the concentration of C9 in pooled serum from 1-d-old rats was only 43 +/- 3.8 microg/mL and increased during the first 3 wk of life to 170 +/- 20 microg/mL. Similarly, the capacities of neonatal rat serum to kill two pathogenic strains of Escherichia coli and to lyse sensitized sheep erythrocytes were diminished compared with adult serum but increased during the first 3 wk of life. Supplemental human C9 significantly enhanced the bactericidal and hemolytic activity of neonatal rat serum. The capacity of neonatal rats to survive after the intrapulmonary injection of E. coli was positively correlated with the serum C9 concentration, bactericidal activity, and hemolytic activity. In 2-d-old rats infected with E. coli, the intraperitoneal administration of human C9 significantly enhanced survival and also enhanced the protective effect of intraperitoneal human IgG antibodies. The data indicate that C9 deficiency predisposed neonatal rats to invasion by E. coli. The neonatal rat appears to be a suitable model with which to investigate the significance of C9 deficiency.
Lassiter
H A
HA
Department of Pediatrics, University of Louisville School of Medicine, Kentucky 40292, USA.
Walz
B M
BM
Wilson
J L
JL
Jung
E
E
Calisi
C R
CR
Goldsmith
L J
LJ
Wilson
R A
RA
Morgan
B P
BP
Feldhoff
R C
RC
D000367:Age Factors; D000818:Animals; D000831:Animals, Newborn; D016470:Bacteremia / Q000276:immunology / Q000628:therapy; D001770:Blood Bactericidal Activity; D003186:Complement C9 / Q000008:administration & dosage* / Q000172:deficiency*; D004195:Disease Models, Animal; D004927:Escherichia coli Infections / Q000276:immunology* / Q000628:therapy*; D006461:Hemolysis; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D066298:In Vitro Techniques; D007274:Injections, Intraperitoneal; D051381:Rats; D017207:Rats, Sprague-Dawley; D018805:Sepsis / Q000276:immunology* / Q000628:therapy*
D003186:Complement C9; D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous